Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Non Operating Income (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Non Operating Income for 8 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 142.01% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.8 million through Dec 2025, up 2390.15% year-over-year, with the annual reading at $93.8 million for FY2025, 2390.15% up from the prior year.
  • Non Operating Income for Q4 2025 was $1.6 million at Whitehawk Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Non Operating Income was $88.2 million in Q1 2025, with the low at -$1.4 million in Q1 2021.
  • Average Non Operating Income over 5 years is $5.4 million, with a median of $1.3 million recorded in 2023.
  • Peak annual rise in Non Operating Income hit 11535.77% in 2021, while the deepest fall reached 807.7% in 2021.
  • Over 5 years, Non Operating Income stood at -$45000.0 in 2021, then soared by 3544.44% to $1.5 million in 2022, then decreased by 6.77% to $1.4 million in 2023, then tumbled by 53.22% to $676000.0 in 2024, then soared by 142.01% to $1.6 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $1.6 million, $1.8 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.